% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{May:148910,
      author       = {V. May and S. Berchtold$^*$ and A. Berger and S. Venturelli
                      and M. Burkard and C. Leischner and N. P. Malek and U. M.
                      Lauer$^*$},
      title        = {{C}hemovirotherapy for pancreatic cancer: {G}emcitabine
                      plus oncolytic measles vaccine virus.},
      journal      = {Oncology letters},
      volume       = {18},
      number       = {5},
      issn         = {1792-1082},
      address      = {Athens},
      publisher    = {Spandidos Publ.},
      reportid     = {DKFZ-2020-00068},
      pages        = {5534-5542},
      year         = {2019},
      note         = {LA:L801},
      abstract     = {Oncolytic virotherapy with vaccine viruses employs
                      replicative vectors, which quite selectively infect tumor
                      cells leading to massive virus replication followed by
                      subsequent profound tumor cell death (oncolysis). Measles
                      vaccine virus (MeV) has already shown great oncolytic
                      activity against different types of cancers, including
                      pancreatic cancer. Gemcitabine is a first line
                      chemotherapeutic drug used for pancreatic cancer in
                      palliative treatment plans. Furthermore, this drug can be
                      used to induce senescence, a permanent cell cycle arrest, in
                      tumor cells. In our preclinical work, three
                      well-characterized immortalized human pancreatic cancer cell
                      lines were used to investigate the combinatorial effect of
                      MeV-based virotherapy together with the chemotherapeutic
                      compound gemcitabine. Viability assays revealed that the
                      combination of only small amounts of MeV together with
                      subtherapeutic concentrations of gemcitabine resulted in a
                      tumor cell mass reduction of $>50\%.$ To further investigate
                      the replication of the oncolytic MeV vectors under these
                      distinct combinatorial conditions, viral growth curves were
                      generated. As a result, viral replication was found to be
                      only slightly diminished in the presence of gemcitabine. As
                      gemcitabine induces senescence, the effect of MeV on that
                      phenomenon was explored using a senescence-associated
                      β-galactosidase assay. Notably, gemcitabine-induced tumor
                      cell senescence was not impaired by MeV. Accordingly, the
                      chemovirotherapeutic combination of gemcitabine plus
                      oncolytic MeV constitutes a novel therapeutic option for
                      advanced pancreatic carcinoma that is characterized by the
                      mutual improvement of the effectiveness of each therapeutic
                      component.},
      cin          = {L801},
      ddc          = {610},
      cid          = {I:(DE-He78)L801-20160331},
      pnm          = {899 - ohne Topic (POF3-899)},
      pid          = {G:(DE-HGF)POF3-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31612061},
      pmc          = {pmc:PMC6781561},
      doi          = {10.3892/ol.2019.10901},
      url          = {https://inrepo02.dkfz.de/record/148910},
}